Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-12-19 |
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Citation ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "179631"] ; # fhir:meta [ fhir:versionId [ fhir:v "9" ] ; fhir:lastUpdated [ fhir:v "2024-11-22T19:14:41.713Z"^^xsd:dateTime ] ; ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Citation 179631</b></p><a name=\"179631\"> </a><a name=\"hc179631\"> </a><a name=\"179631-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 9; Last updated: 2024-11-22 19:14:41+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-journal-article-citation.html\">JournalArticleCitation</a></p></div><p><b>url</b>: <a href=\"Citation-179631.html\">Citation 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/179631, <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421, <a href=\"http://terminology.hl7.org/6.1.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.42</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-12-19 14:29:51+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use\">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}\">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title=\"Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}\">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>approvalDate</b>: 2009-01-13</p><p><b>lastReviewDate</b>: 2023-02-02</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type citation-source}\">Citation Source</span></p><p><b>classifier</b>: <span title=\"Codes:\">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}\">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}\">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type medline-medline}\">Medline Citation Status of Medline</span>, <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-ppublish}\">PubMed PublicationStatus of ppublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}\">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}\">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2009-01-14 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}\">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pmc-release}\">PubMed Pubstatus of PMC release</span></p><p><b>period</b>: ?? --> 2009-12-20</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC3864402, <code>https://doi.org</code>/10.1200/JCO.2007.15.9830, pii/JCO.2007.15.9830</p><h3>Titles</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/title-type primary}\">Primary title</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></td><td><div><p>Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p>\n</div></td></tr></table><h3>Abstracts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p><strong>PURPOSE:</strong> We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n<strong>PATIENTS AND METHODS:</strong> Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n<strong>RESULTS:</strong> Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n<strong>CONCLUSION:</strong> There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.</p>\n</div></td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/17237035/\">https://pubmed.ncbi.nlm.nih.gov/17237035/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/17237035</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/7679039/\">https://pubmed.ncbi.nlm.nih.gov/7679039/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/7679039</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11027418/\">https://pubmed.ncbi.nlm.nih.gov/11027418/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11027418</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9815636/\">https://pubmed.ncbi.nlm.nih.gov/9815636/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9815636</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10561202/\">https://pubmed.ncbi.nlm.nih.gov/10561202/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10561202</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11134194/\">https://pubmed.ncbi.nlm.nih.gov/11134194/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11134194</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/12610188/\">https://pubmed.ncbi.nlm.nih.gov/12610188/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/12610188</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15470214/\">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15470213/\">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15470213</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/6337697/\">https://pubmed.ncbi.nlm.nih.gov/6337697/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/6337697</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/3523938/\">https://pubmed.ncbi.nlm.nih.gov/3523938/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/3523938</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/2213104/\">https://pubmed.ncbi.nlm.nih.gov/2213104/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/2213104</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9267791/\">https://pubmed.ncbi.nlm.nih.gov/9267791/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9267791</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9123707/\">https://pubmed.ncbi.nlm.nih.gov/9123707/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9123707</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9619712/\">https://pubmed.ncbi.nlm.nih.gov/9619712/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9619712</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10472324/\">https://pubmed.ncbi.nlm.nih.gov/10472324/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10472324</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10524892/\">https://pubmed.ncbi.nlm.nih.gov/10524892/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10524892</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11256836/\">https://pubmed.ncbi.nlm.nih.gov/11256836/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11256836</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/14706014/\">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/14706014</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/16921051/\">https://pubmed.ncbi.nlm.nih.gov/16921051/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/16921051</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/16170163/\">https://pubmed.ncbi.nlm.nih.gov/16170163/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/16170163</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10694556/\">https://pubmed.ncbi.nlm.nih.gov/10694556/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10694556</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18207190/\">https://pubmed.ncbi.nlm.nih.gov/18207190/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18207190</p></blockquote><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/published-in-type D020492}\">Periodical</span></p><p><b>identifier</b>: Electronic ISSN Type/1527-7755, ISOAbbreviation/J Clin Oncol, ISSN Linking/0732-183X, Medline Title Abbreviation/J Clin Oncol, NLM Unique ID/8309333</p><p><b>title</b>: Journal of clinical oncology : official journal of the American Society of Clinical Oncology</p><p><b>publisherLocation</b>: United States</p></blockquote><p><b>citedMedium</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-medium internet}\">Internet</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 36</p><p><b>articleDate</b>: 2008-12-20</p><p><b>publicationDateText</b>: 2008-Dec-20</p><p><b>language</b>: <span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></p><p><b>pageString</b>: 5936-42</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-medium internet-without-issue}\">Internet without issue</span></p><p><b>articleDate</b>: 2008-11-24</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}\">Abstract</span></p><p><b>url</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/19029421/\">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/artifact-url-classifier doi-based}\">DOI Based</span></p><p><b>url</b>: <a href=\"https://doi.org/10.1200/JCO.2007.15.9830\">https://doi.org/10.1200/JCO.2007.15.9830</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}\">Publishing Model</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier Print-Electronic}\">Print Electronic</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}\">Chemical</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000726}\">Androgen Antagonists</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000903}\">Antibiotics, Antineoplastic</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D018906}\">Antineoplastic Agents, Alkylating</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000972}\">Antineoplastic Agents, Phytogenic</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 35LT29625A}, {https://meshb.nlm.nih.gov/ D004961}\">Estramustine</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 5V9KLZ54CY}, {https://meshb.nlm.nih.gov/ D014747}\">Vinblastine</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 80168379AG}, {https://meshb.nlm.nih.gov/ D004317}\">Doxorubicin</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances R9400W927I}, {https://meshb.nlm.nih.gov/ D007654}\">Ketoconazole</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href=\"#hc179631/meshHeading0\">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}\">Publication type</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D017428}\">Clinical Trial, Phase III</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016428}\">Journal Article</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016449}\">Randomized Controlled Trial</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}\">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}\">Citation subset</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}\">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor0\">Millikan RE</a></p><p><b>forenameInitials</b>: RE</p><p><b>affiliation</b>: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor1\">Wen S</a></p><p><b>forenameInitials</b>: S</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor2\">Pagliaro LC</a></p><p><b>forenameInitials</b>: LC</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor3\">Brown MA</a></p><p><b>forenameInitials</b>: MA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor4\">Moomey B</a></p><p><b>forenameInitials</b>: B</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor5\">Do KA</a></p><p><b>forenameInitials</b>: KA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor6\">Logothetis CJ</a></p><p><b>forenameInitials</b>: CJ</p></blockquote></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor0</b></p><a name=\"179631/contributor0\"> </a><a name=\"hc179631/contributor0\"> </a><a name=\"179631/contributor0-en-US\"> </a><p><b>name</b>: Randall E Millikan </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor1</b></p><a name=\"179631/contributor1\"> </a><a name=\"hc179631/contributor1\"> </a><a name=\"179631/contributor1-en-US\"> </a><p><b>name</b>: Sijin Wen </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor2</b></p><a name=\"179631/contributor2\"> </a><a name=\"hc179631/contributor2\"> </a><a name=\"179631/contributor2-en-US\"> </a><p><b>name</b>: Lance C Pagliaro </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor3</b></p><a name=\"179631/contributor3\"> </a><a name=\"hc179631/contributor3\"> </a><a name=\"179631/contributor3-en-US\"> </a><p><b>name</b>: Melissa A Brown </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor4</b></p><a name=\"179631/contributor4\"> </a><a name=\"hc179631/contributor4\"> </a><a name=\"179631/contributor4-en-US\"> </a><p><b>name</b>: Brenda Moomey </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor5</b></p><a name=\"179631/contributor5\"> </a><a name=\"hc179631/contributor5\"> </a><a name=\"179631/contributor5-en-US\"> </a><p><b>name</b>: Kim-Anh Do </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor6</b></p><a name=\"179631/contributor6\"> </a><a name=\"hc179631/contributor6\"> </a><a name=\"179631/contributor6-en-US\"> </a><p><b>name</b>: Christopher J Logothetis </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name=\"179631/meshHeading0\"> </a><a name=\"hc179631/meshHeading0\"> </a><a name=\"179631/meshHeading0-en-US\"> </a><p><b>artifact</b>: <a href=\"#hc179631\">Citation 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</a></p><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000328}\">Adult</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000368}\">Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000369}\">Aged, 80 and over</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000726}\">Androgen Antagonists</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000903}\">Antibiotics, Antineoplastic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D018906}\">Antineoplastic Agents, Alkylating</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000972}\">Antineoplastic Agents, Phytogenic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000971}\">Antineoplastic Combined Chemotherapy Protocols</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D004317}\">Doxorubicin</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D004961}\">Estramustine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D006801}\">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D007654}\">Ketoconazole</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D008297}\">Male</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D008875}\">Middle Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D009362}\">Neoplasm Metastasis</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D011471}\">Prostatic Neoplasms</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000188}\">drug therapy</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000401}\">mortality</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D014747}\">Vinblastine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote></blockquote></div>" ] ; # fhir:contained ( [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor0" ] ; ( fhir:name [ fhir:family [ fhir:v "Millikan" ] ; ( fhir:given [ fhir:v "Randall E" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor1" ] ; ( fhir:name [ fhir:family [ fhir:v "Wen" ] ; ( fhir:given [ fhir:v "Sijin" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor2" ] ; ( fhir:name [ fhir:family [ fhir:v "Pagliaro" ] ; ( fhir:given [ fhir:v "Lance C" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor3" ] ; ( fhir:name [ fhir:family [ fhir:v "Brown" ] ; ( fhir:given [ fhir:v "Melissa A" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor4" ] ; ( fhir:name [ fhir:family [ fhir:v "Moomey" ] ; ( fhir:given [ fhir:v "Brenda" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor5" ] ; ( fhir:name [ fhir:family [ fhir:v "Do" ] ; ( fhir:given [ fhir:v "Kim-Anh" ] ) ] ) ] [ a fhir:Practitioner ; fhir:id [ fhir:v "contributor6" ] ; ( fhir:name [ fhir:family [ fhir:v "Logothetis" ] ; ( fhir:given [ fhir:v "Christopher J" ] ) ] ) ] [ a fhir:ArtifactAssessment ; fhir:id [ fhir:v "meshHeading0" ] ; fhir:artifact [ a fhir:Reference ; fhir:reference [ fhir:v "#" ] ; fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ] ; ( fhir:content [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000328" ] ; fhir:display [ fhir:v "Adult" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000368" ] ; fhir:display [ fhir:v "Aged" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000369" ] ; fhir:display [ fhir:v "Aged, 80 and over" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000726" ] ; fhir:display [ fhir:v "Androgen Antagonists" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000627" ] ; fhir:display [ fhir:v "therapeutic use" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49488" ] ; fhir:display [ fhir:v "Yes" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000903" ] ; fhir:display [ fhir:v "Antibiotics, Antineoplastic" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D018906" ] ; fhir:display [ fhir:v "Antineoplastic Agents, Alkylating" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000972" ] ; fhir:display [ fhir:v "Antineoplastic Agents, Phytogenic" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000971" ] ; fhir:display [ fhir:v "Antineoplastic Combined Chemotherapy Protocols" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000627" ] ; fhir:display [ fhir:v "therapeutic use" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49488" ] ; fhir:display [ fhir:v "Yes" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D004317" ] ; fhir:display [ fhir:v "Doxorubicin" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D004961" ] ; fhir:display [ fhir:v "Estramustine" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D006801" ] ; fhir:display [ fhir:v "Humans" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D007654" ] ; fhir:display [ fhir:v "Ketoconazole" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D008297" ] ; fhir:display [ fhir:v "Male" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D008875" ] ; fhir:display [ fhir:v "Middle Aged" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D009362" ] ; fhir:display [ fhir:v "Neoplasm Metastasis" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D011471" ] ; fhir:display [ fhir:v "Prostatic Neoplasms" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000188" ] ; fhir:display [ fhir:v "drug therapy" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49488" ] ; fhir:display [ fhir:v "Yes" ] ] ) ] ) ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000401" ] ; fhir:display [ fhir:v "mortality" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ; fhir:text [ fhir:v "components (if present) include qualifier codings" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D014747" ] ; fhir:display [ fhir:v "Vinblastine" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; fhir:freeToShare [ fhir:v "true"^^xsd:boolean ] ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ fhir:text [ fhir:v "is not a major topic" ] ] ) ] [ fhir:type [ fhir:text [ fhir:v "qualifier" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "Q000008" ] ; fhir:display [ fhir:v "administration & dosage" ] ] ) ] ) ; ( fhir:component [ fhir:type [ fhir:text [ fhir:v "is Major topic" ] ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://ncithesaurus.nci.nih.gov/ncitbrowser"^^xsd:anyURI ] ; fhir:code [ fhir:v "C49487" ] ; fhir:display [ fhir:v "No" ] ] ) ] ) ] ) ] ) ] ) ] ) ; # fhir:url [ fhir:v "https://fevir.net/resources/Citation/179631"^^xsd:anyURI] ; # fhir:identifier ( [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "ACSN" ] ; fhir:display [ fhir:v "Accession ID" ] ] ) ; fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ; fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ; fhir:value [ fhir:v "https://fevir.net/FOI/179631" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "19029421" ] ] [ fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ; fhir:value [ fhir:v "urn:oid:2.16.840.1.113883.4.642.40.44.15.42" ] ] ) ; # fhir:version [ fhir:v "2.0.0-ballot"] ; # fhir:title [ fhir:v "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."] ; # fhir:status [ fhir:v "active"] ; # fhir:date [ fhir:v "2024-12-19T14:29:51+00:00"^^xsd:dateTime] ; # fhir:publisher [ fhir:v "HL7 International / Clinical Decision Support"] ; # fhir:contact ( [ fhir:name [ fhir:v "HL7 International / Clinical Decision Support" ] ; ( fhir:telecom [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "http://www.hl7.org/Special/committees/dss" ] ] ) ] ) ; # fhir:description [ fhir:v "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."] ; # fhir:useContext ( [ fhir:code [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "fevir-platform-use" ] ; fhir:display [ fhir:v "FEvIR Platform Use" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "medline-base" ] ; fhir:display [ fhir:v "Medline Base" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ] ) ; # fhir:jurisdiction ( [ ( fhir:coding [ fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ] ; fhir:code [ fhir:v "001" ] ; fhir:display [ fhir:v "World" ] ] ) ] ) ; # fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # fhir:approvalDate [ fhir:v "2009-01-13"^^xsd:date] ; # fhir:lastReviewDate [ fhir:v "2023-02-02"^^xsd:date] ; # fhir:author ( [ fhir:name [ fhir:v "Computable Publishing®: MEDLINE-to-FEvIR Converter" ] ] ) ; # fhir:classification ( [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "citation-source" ] ; fhir:display [ fhir:v "Citation Source" ] ] ) ] ; ( fhir:classifier [ fhir:text [ fhir:v "MEDLINE" ] ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "medline-owner" ] ; fhir:display [ fhir:v "MEDLINE Citation Owner" ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"^^xsd:anyURI ] ; fhir:code [ fhir:v "NLM" ] ; fhir:display [ fhir:v "National Library of Medicine, Index Section" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ] ) ; # fhir:currentState ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "medline-medline" ] ; fhir:display [ fhir:v "Medline Citation Status of Medline" ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "pubmed-publication-status-ppublish" ] ; fhir:display [ fhir:v "PubMed PublicationStatus of ppublish" ] ] ) ] ) ; # fhir:statusDate ( [ fhir:activity [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "pubmed-pubstatus-pubmed" ] ; fhir:display [ fhir:v "PubMed Pubstatus of Pubmed" ] ] ) ] ; fhir:period [ fhir:end [ fhir:v "2008-11-26T09:00:00.000Z"^^xsd:dateTime ] ] ] [ fhir:activity [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "pubmed-pubstatus-medline" ] ; fhir:display [ fhir:v "PubMed Pubstatus of Medline" ] ] ) ] ; fhir:period [ fhir:end [ fhir:v "2009-01-14T09:00:00.000Z"^^xsd:dateTime ] ] ] [ fhir:activity [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "pubmed-pubstatus-entrez" ] ; fhir:display [ fhir:v "PubMed Pubstatus of Entrez" ] ] ) ] ; fhir:period [ fhir:end [ fhir:v "2008-11-26T09:00:00.000Z"^^xsd:dateTime ] ] ] [ fhir:activity [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "pubmed-pubstatus-pmc-release" ] ; fhir:display [ fhir:v "PubMed Pubstatus of PMC release" ] ] ) ] ; fhir:period [ fhir:end [ fhir:v "2009-12-20"^^xsd:date ] ] ] ) ; # fhir:citedArtifact [ ( fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "19029421" ] ] [ fhir:system [ fhir:v "https://www.ncbi.nlm.nih.gov/pmc/"^^xsd:anyURI ] ; fhir:value [ fhir:v "PMC3864402" ] ] [ fhir:system [ fhir:v "https://doi.org"^^xsd:anyURI ] ; fhir:value [ fhir:v "10.1200/JCO.2007.15.9830" ] ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "ACSN" ] ; fhir:display [ fhir:v "Accession ID" ] ] ) ; fhir:text [ fhir:v "pii" ] ] ; fhir:value [ fhir:v "JCO.2007.15.9830" ] ] ) ; ( fhir:title [ ( fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/title-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "primary" ] ; fhir:display [ fhir:v "Primary title" ] ] ) ] ) ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "English" ] ] ) ] ; fhir:text [ fhir:v "Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer." ] ] ) ; ( fhir:abstract [ fhir:text [ fhir:v "**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype." ] ] ) ; ( fhir:relatesTo [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/17237035/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "17237035" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/7679039/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "7679039" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/11027418/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "11027418" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/9815636/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "9815636" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/10561202/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "10561202" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/11134194/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "11134194" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/12610188/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "12610188" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/15470214/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "15470214" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/15470213/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "15470213" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/6337697/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "6337697" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/3523938/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "3523938" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/2213104/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "2213104" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/9267791/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "9267791" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/9123707/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "9123707" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/9619712/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "9619712" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/10472324/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "10472324" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/10524892/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "10524892" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/11256836/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "11256836" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/14706014/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "14706014" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; fhir:citation [ fhir:v "Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993" ] ] [ fhir:type [ fhir:v "cites" ] ; fhir:citation [ fhir:v "Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979" ] ] [ fhir:type [ fhir:v "cites" ] ; fhir:citation [ fhir:v "Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982" ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/16921051/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "16921051" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/16170163/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "16170163" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/10694556/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "10694556" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] [ fhir:type [ fhir:v "cites" ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ] ) ] ) ; fhir:citation [ fhir:v "Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008" ] ; fhir:document [ fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/18207190/"^^xsd:anyURI ] ] ; fhir:resourceReference [ fhir:identifier [ fhir:system [ fhir:v "https://pubmed.ncbi.nlm.nih.gov"^^xsd:anyURI ] ; fhir:value [ fhir:v "18207190" ] ; fhir:assigner [ fhir:display [ fhir:v "NLM" ] ] ] ] ] ) ; ( fhir:publicationForm [ fhir:publishedIn [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/published-in-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "D020492" ] ; fhir:display [ fhir:v "Periodical" ] ] ) ] ; ( fhir:identifier [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"^^xsd:anyURI ] ; fhir:code [ fhir:v "Electronic" ] ; fhir:display [ fhir:v "Electronic" ] ] ) ; fhir:text [ fhir:v "Electronic ISSN Type" ] ] ; fhir:system [ fhir:v "https://portal.issn.org"^^xsd:anyURI ] ; fhir:value [ fhir:v "1527-7755" ] ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "XX" ] ; fhir:display [ fhir:v "Organization identifier" ] ] ) ; fhir:text [ fhir:v "ISOAbbreviation" ] ] ; fhir:system [ fhir:v "https://www.issn.org/services/online-services/access-to-the-ltwa/"^^xsd:anyURI ] ; fhir:value [ fhir:v "J Clin Oncol" ] ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "XX" ] ; fhir:display [ fhir:v "Organization identifier" ] ] ) ; fhir:text [ fhir:v "ISSN Linking" ] ] ; fhir:system [ fhir:v "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"^^xsd:anyURI ] ; fhir:value [ fhir:v "0732-183X" ] ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "XX" ] ; fhir:display [ fhir:v "Organization identifier" ] ] ) ; fhir:text [ fhir:v "Medline Title Abbreviation" ] ] ; fhir:system [ fhir:v "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"^^xsd:anyURI ] ; fhir:value [ fhir:v "J Clin Oncol" ] ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "XX" ] ; fhir:display [ fhir:v "Organization identifier" ] ] ) ; fhir:text [ fhir:v "NLM Unique ID" ] ] ; fhir:system [ fhir:v "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"^^xsd:anyURI ] ; fhir:value [ fhir:v "8309333" ] ] ) ; fhir:title [ fhir:v "Journal of clinical oncology : official journal of the American Society of Clinical Oncology" ] ; fhir:publisherLocation [ fhir:v "United States" ] ] ; fhir:citedMedium [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-medium"^^xsd:anyURI ] ; fhir:code [ fhir:v "internet" ] ; fhir:display [ fhir:v "Internet" ] ] ) ] ; fhir:volume [ fhir:v "26" ] ; fhir:issue [ fhir:v "36" ] ; fhir:articleDate [ fhir:v "2008-12-20"^^xsd:date ] ; fhir:publicationDateText [ fhir:v "2008-Dec-20" ] ; ( fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "English" ] ] ) ] ) ; fhir:pageString [ fhir:v "5936-42" ] ] [ fhir:citedMedium [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-medium"^^xsd:anyURI ] ; fhir:code [ fhir:v "internet-without-issue" ] ; fhir:display [ fhir:v "Internet without issue" ] ] ) ] ; fhir:articleDate [ fhir:v "2008-11-24"^^xsd:date ] ] ) ; ( fhir:webLocation [ ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/artifact-url-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "abstract" ] ; fhir:display [ fhir:v "Abstract" ] ] ) ] ) ; fhir:url [ fhir:v "https://pubmed.ncbi.nlm.nih.gov/19029421/"^^xsd:anyURI ] ] [ ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/artifact-url-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "doi-based" ] ; fhir:display [ fhir:v "DOI Based" ] ] ) ] ) ; fhir:url [ fhir:v "https://doi.org/10.1200/JCO.2007.15.9830"^^xsd:anyURI ] ] ) ; ( fhir:classification [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "publishing-model" ] ; fhir:display [ fhir:v "Publishing Model" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "Print-Electronic" ] ; fhir:display [ fhir:v "Print Electronic" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "chemical" ] ; fhir:display [ fhir:v "Chemical" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000726" ] ; fhir:display [ fhir:v "Androgen Antagonists" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000903" ] ; fhir:display [ fhir:v "Antibiotics, Antineoplastic" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D018906" ] ; fhir:display [ fhir:v "Antineoplastic Agents, Alkylating" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D000972" ] ; fhir:display [ fhir:v "Antineoplastic Agents, Phytogenic" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://www.cas.org/support/documentation/chemical-substances"^^xsd:anyURI ] ; fhir:code [ fhir:v "35LT29625A" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D004961" ] ; fhir:display [ fhir:v "Estramustine" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://www.cas.org/support/documentation/chemical-substances"^^xsd:anyURI ] ; fhir:code [ fhir:v "5V9KLZ54CY" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D014747" ] ; fhir:display [ fhir:v "Vinblastine" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://www.cas.org/support/documentation/chemical-substances"^^xsd:anyURI ] ; fhir:code [ fhir:v "80168379AG" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D004317" ] ; fhir:display [ fhir:v "Doxorubicin" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://www.cas.org/support/documentation/chemical-substances"^^xsd:anyURI ] ; fhir:code [ fhir:v "R9400W927I" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D007654" ] ; fhir:display [ fhir:v "Ketoconazole" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "mesh-heading" ] ; fhir:display [ fhir:v "MeSH heading" ] ] ) ] ; ( fhir:artifactAssessment [ fhir:reference [ fhir:v "#meshHeading0" ] ; fhir:type [ fhir:v "ArtifactAssessment"^^xsd:anyURI ] ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "publication-type" ] ; fhir:display [ fhir:v "Publication type" ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D017428" ] ; fhir:display [ fhir:v "Clinical Trial, Phase III" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] [ ( fhir:coding [ fhir:system [ fhir:v "https://meshb.nlm.nih.gov/"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016449" ] ; fhir:display [ fhir:v "Randomized Controlled Trial" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "knowledge-artifact-type" ] ; fhir:display [ fhir:v "Knowledge Artifact Type" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/citation-artifact-classifier"^^xsd:anyURI ] ; fhir:code [ fhir:v "D016428" ] ; fhir:display [ fhir:v "Journal Article" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ; ( fhir:artifactAssessment [ fhir:display [ fhir:v "Classifier added by Computable Publishing LLC" ] ] ) ] [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/cited-artifact-classification-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "citation-subset" ] ; fhir:display [ fhir:v "Citation subset" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ; ( fhir:classifier [ ( fhir:coding [ fhir:system [ fhir:v "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"^^xsd:anyURI ] ; fhir:code [ fhir:v "IM" ] ; fhir:display [ fhir:v "IM" ] ; fhir:userSelected [ fhir:v "false"^^xsd:boolean ] ] ) ] ) ] ) ; fhir:contributorship [ fhir:complete [ fhir:v "true"^^xsd:boolean ] ; ( fhir:entry [ fhir:contributor [ fhir:reference [ fhir:v "#contributor0" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Millikan RE" ] ] ; fhir:forenameInitials [ fhir:v "RE" ] ; ( fhir:affiliation [ fhir:display [ fhir:v "Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org" ] ] ) ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor1" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Wen S" ] ] ; fhir:forenameInitials [ fhir:v "S" ] ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor2" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Pagliaro LC" ] ] ; fhir:forenameInitials [ fhir:v "LC" ] ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor3" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Brown MA" ] ] ; fhir:forenameInitials [ fhir:v "MA" ] ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor4" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Moomey B" ] ] ; fhir:forenameInitials [ fhir:v "B" ] ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor5" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Do KA" ] ] ; fhir:forenameInitials [ fhir:v "KA" ] ] [ fhir:contributor [ fhir:reference [ fhir:v "#contributor6" ] ; fhir:type [ fhir:v "Practitioner"^^xsd:anyURI ] ; fhir:display [ fhir:v "Logothetis CJ" ] ] ; fhir:forenameInitials [ fhir:v "CJ" ] ] ) ] ] . #
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change